(Q46684956)

24 December 2017

title

Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer (English)

1 reference

24 December 2017

1

Anthony V D'Amico

1 reference

24 December 2017

author name string

Ming-Hui Chen

2

1 reference

24 December 2017

Michael C Cox

3

1 reference

24 December 2017

William Dahut

4

1 reference

24 December 2017

William D Figg

5

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

24 December 2017

published in

Urology

1 reference

24 December 2017

volume

66

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

571-576

1 reference

24 December 2017

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.03.083

10.1016/J.UROLOGY.2005.03.083

7 January 2021

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017